Sugi Predict

Sugi Predict / Compounds / SCHEMBL14741306

SCHEMBL14741306

SCHEMBL14741306

Nc1cc(Cl)c(Br)cc1I

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 3/20 0.44
▸ GAA P10253 2/20 0.43
▸ CD44 P16070 1/20 0.36
▸ CA1 P00915 5/20 0.35
▸ CA2 P00918 5/20 0.35
▸ CA9 Q16790 5/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA4 P22748 2/20 0.34
▸ CA6 P23280 2/20 0.34
▸ CA5A P35218 2/20 0.34
▸ CA7 P43166 2/20 0.34
▸ CA14 Q9ULX7 2/20 0.34
▸ CA5B Q9Y2D0 2/20 0.34
▸ CA3 P07451 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.32
▸ TSHR P16473 3/20 0.31
▸ CYP3A4 P08684 2/20 0.31
▸ TP53 P04637 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16069461 0.91 AHR (0.44) AHRGAACD44CA1CA2
SCHEMBL231150 0.79 GAA (0.53) AHRGAACD44CA1CA2
SCHEMBL29589945 0.79 GAA (0.53) AHRGAACD44CA1CA2
SCHEMBL2766461 0.79 GAA (0.53) AHRGAACD44CA1CA2
SCHEMBL9629823 0.77 GAA (0.67) AHRGAACD44CA1CA2
SCHEMBL16555486 0.77 GAA (0.50) AHRGAACD44CA1CA2
SCHEMBL1770635 0.73 CD44 (0.54) AHRGAACD44CA1CA2
SCHEMBL23974410 0.72 GAA (0.58) AHRGAACD44CA1CA2
SCHEMBL22289313 0.71 AHR (0.39) AHRCSNK2A1ALDH1A1
SCHEMBL22560894 0.71 TSHR (0.40) AHRCA1CA2CA9CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 2026-03-05 — — US disclosed
EP-4647424-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-11-12 — — EP disclosed
WO-2025089480-A1 COMPOUND, AND ORGANIC LIGHT-EMITTING DEVICE AND COMPOSITION FOR ORGANIC LAYER WHICH COMPRISE SAME 엘티소재주식회사 2025-05-01 — — WO disclosed
CN-118724728-A Organic compound, organic electroluminescent device and electronic apparatus 陕西莱特光电材料股份有限公司 2024-10-01 — — CN disclosed
WO-2024181437-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY 中外製薬株式会社 2024-09-06 — — WO disclosed
EP-3862350-B1 NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME LG CHEMICAL LTD (KR) 2024-06-12 — — EP disclosed
CN-112888683-B Novel compound and organic light emitting device comprising the same 株式会社LG化学 2024-04-16 — — CN disclosed
US-11910711-B2 Cyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2024-02-20 — — US disclosed
EP-4266390-A1 ORGANIC LIGHT EMITTING DEVICE Lg Chem, Ltd. (KR) 2023-10-25 — — EP disclosed
EP-4209492-A1 COMPOUND FOR TREATING THROMBOTIC DISEASES Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2023-07-12 — — EP disclosed
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 — — EP disclosed
EP-2970119-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS Merck Sharp & Dohme Corp. (US) 2016-01-20 — — EP disclosed
US-20160002224-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2016-01-07 — — US disclosed
US-20160002224-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2016-01-07 — — US disclosed
US-20160002224-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2016-01-07 — — US disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 — — US disclosed
WO-2014139388-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2014-09-18 — — WO disclosed
WO-2014139388-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2014-09-18 — — WO disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 — — EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062412-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY MYT1, NTMT1, MYL6 AHR 2308/4885GAA 3566/4885CD44 4804/4885
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP AHR 4708/4885GAA 91/4885CD44 1306/4885
US-11910711-B2 Cyclic compound and organic light emitting device comprising same CRY1, CRY2, CYBA AHR 1388/4885GAA 3807/4885CD44 3975/4885
US-20160002224-A1 NOVEL INDOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS GPR119, PRKAG2, PRKAG1 AHR 1066/4885GAA 2126/4885CD44 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.